FDA Approves Phase I/II Study for Revolutionary HIV and AIDS Treatment Cytolin

Strategic Insights -

The U.S. Food and Drug Administration (FDA) has granted permission to Amerimmune, Inc. to test its revolutionary treatment Cytolin in a Phase I/II study in HIV-infected individuals. The study aims to evaluate the safety, tolerability, and efficacy of Cytolin, a patented monoclonal antibody that blocks certain adhesion molecules on immune system cells, protecting the body from "killer-type" T cells that can damage the immune system. The study, led by Victor L. Beer, MD, at his Los Angeles clinic, will enroll 24 patients and assess the biological effects of various doses of Cytolin.

Key Takeaways:

  • The FDA has approved a Phase I/II study for Cytolin, a treatment for HIV and AIDS patients, which will assess the safety, tolerability, and efficacy of the monoclonal antibody.
  • The study will be conducted at the clinic of Victor L. Beer, MD, in Los Angeles, California, and will involve 24 patients.
  • Cytolin blocks certain adhesion molecules on immune system cells, protecting the body from "killer-type" T cells that can damage the immune system.
  • Amerimmune plans to commence patient recruitment and begin the trial in September 1999, with an anticipated duration of approximately five to six months.
  • A Phase II/III study may follow the Phase I/II trial to determine the effectiveness of Cytolin in a wider range of patients and identify potential side effects.
  • Cytolin is a distinct therapeutic approach from antiviral drugs, which target the virus directly.

Statistics:

  • 24 patients will be enrolled in the Phase I/II study.
  • The study is expected to last approximately five to six months.
  • Patient recruitment began prior to the study's initiation in September 1999.
  • Cytolin is a patented monoclonal antibody.

Sources:

  • "Amerimmune, Inc. Announces FDA Approval for Phase I/II Study of Cytolin in HIV Infected Individuals," Amerimmune, Inc. Press Release.
  • Beer, Victor L. MD, Principal Investigator, speaks on the Phase I/II trial, Los Angeles, California, clinic.